FDA’s Arcoxia Decision Offers New Evidence Of Conservative Review Stance
Executive Summary
FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency
You may also be interested in...
Takeda Febuxostat Benefits Outweigh CV Risk; Will Other Gout Drugs Follow?
Strong efficacy data and a desperate need for new gout therapies outweigh the potential cardiovascular risk associated with Takeda's febuxostat, an FDA advisory committee determined in recommending approval of the drug during a Nov. 24 meeting
Takeda Febuxostat Benefits Outweigh CV Risk; Will Other Gout Drugs Follow?
Strong efficacy data and a desperate need for new gout therapies outweigh the potential cardiovascular risk associated with Takeda's febuxostat, an FDA advisory committee determined in recommending approval of the drug during a Nov. 24 meeting
Merck, Wyeth Weather Stormy Q2 Despite Setbacks; Not All Fare So Well
Pharmaceutical companies had a relatively stable second quarter, despite several high-profile regulatory setbacks and failures during the period